|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Switzerland
Espicom Business Intelligence Ltd, Sep 2009, Pages: 84
This in-depth pharmaceutical market report is ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Executive Summary
Switzerland is one of Western Europe’s smaller countries, but is arguably the world’s richest healthcare market. Spending per capita is the highest in Europe, at US$6,569 in 2009. The country has a comprehensive mixture of private and public health provision, funded principally through social insurance. The pharmaceutical market is equally wealthy, amounting to US$7.0 billion, or US$898 per capita.
The Swiss government has been as keen as any other in recent years to contain costs in the healthcare sector. In a country where regions traditionally have a high degree of autonomy, central oversight of health has been increased. A number of specific measures have been taken to rein in costs, and the promotion of generics has been at the forefront, with spectacular success since 2001. The generic market grew very rapidly between 2002 and 2006.
The Swiss pharmaceutical industry is highly advanced and has long has an international reputation for the quality of its production and research. Two companies dominate the sector; Novartis and Roche. They are both prominent in the domestic market, although the majority of their sales are earned outside Switzerland. Swiss exports of pharmaceutical products exceeded US$35 billion in 2007.
Switzerland is not a member of the European Union, but has aligned much of its regulatory system with EU directives. Intellectual property provision is also in line with WTO norms.
Customers who bought this item also bought
The Medical Device Market: Switzerland
The Pharmaceutical Market: Portugal
The Pharmaceutical Market: Mexico
The Pharmaceutical Market: Thailand
The Pharmaceutical Market: Netherlands
The Pharmaceutical Market: Russia
Understanding the Global Pharmaceutical Market
The Pharmaceutical Market: Saudi Arabia
The Pharmaceutical Market: Poland
The Pharmaceutical Market: Sweden
The Pharmaceutical Market: Ukraine
The Pharmaceutical Market: Greece
|
|
|
|
